Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912)
Authors:
- 27 June 2021
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (12) , 7855-7863
Abstract
Background Clinical guidelines recommend altering chemotherapy treatment by decreasing, delaying, or discontinuing dosing in patients who are experiencing chemotherapy-induced peripheral neuropathy. There are few data available on the clinical use of treatment alteration including the severity of CIPN at the time of treatment alteration. Methods This was a retrospective analysis of patients receiving oxaliplatin on the NCCTG N08CB trial. Neuropathy severity was assessed at each cycle by clinicians and patients. Patients were classified as (1) completed treatment without alteration, (2) dose reduction or delay due to neuropathy, (3) discontinuation due to neuropathy, (4) discontinuation for other toxicity, or (5) discontinuation for another reason (5). Comparisons focused primarily on patients with alteration due to neuropathy (groups 2 and/or 3) compared with patients who completed treatment without alteration (group 1). Results In 350 participants, 135 (39%) completed treatment without alteration, 70 (20%) had a dose reduction or delay due to neuropathy, and 35 (10%) discontinued early due to neuropathy. Clinician-assessed neuropathy severity was greater in patients at the time of dose reduction or delay compared with severity at the end of treatment in patients without alteration (p < 0.0001). Patient-reported neuropathy severity at cycle 4 was worse in patients who eventually had a reduction or delay as compared with patients who completed treatment without alteration (p = 0.017). Conclusions Treatment alterations due to neuropathy are common in patients receiving oxaliplatin for colon cancer and are associated with clinician-assessed neuropathy severity. Rapid increases in patient-reported neuropathy severity indicate a potential need for monitoring and intervention. Trial Registration Clinicaltrials.gov Identifier: NCT01099449 (NCCTG N08CB)Keywords
All Related Versions
Funding Information
- National Institutes of Health (UG1CA189823, UG1CA232760)
This publication has 27 references indexed in Scilit:
- Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimensCancer Medicine, 2016
- Patient-reported outcomes in the evaluation of toxicity of anticancer treatmentsNature Reviews Clinical Oncology, 2016
- Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)Journal of Clinical Oncology, 2015
- Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registryActa Oncologica, 2015
- Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)Journal of Clinical Oncology, 2014
- Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patientsJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 QuestionnaireQuality of Life Research, 2013
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical OutcomesJNCI: Journal of the National Cancer Institute, 2009
- A Questionnaire Survey of Physicians' Perspectives Regarding the Assessment of Chemotherapy-induced Peripheral Neuropathy in Patients with Breast CancerJapanese Journal of Clinical Oncology, 2008
- The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20European Journal of Cancer, 2005